Samsung Electronics Shares Jump on HBM4 Mass Production Report 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
NEW ORLEANS, March 28, 2018 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (Nasdaq:SLDB), if they purchased the Company’s shares between January 25, 2018, and March 14, 2018 (the “Class Period”) or in its January 25, 2018 initial public offering (“IPO”). This action is pending in the United States District Court for the District of Massachusetts.
What You May Do
If you purchased shares of Solid Biosciences and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-sldb/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 28, 2018.
About the Lawsuit
Solid Biosciences and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On January 30, 2018, a report co-authored by a former scientific advisor of the Company revealed risks of high systemic dosing using the Company’s delivery system, AAV or adeno-associated virus, for its lead drug candidate SGT-001. Then, on March 14, 2018, the Company disclosed a clinical hold placed on the SGT-001 trial by the FDA relating to adverse events.
On this news, the price of Solid Biosciences’ shares plummeted over 60% to $9.32/share on March 15, 2018.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447
